This study was conducted to investigate the serum levels of her-2/neu and survivin in patients with early-stage breast cancer and their relationship with known histological parameters. Forty-one patients with early-stage breast cancer were investigated. Serum samples were collected from patients on their first admission before adjuvant chemotherapy, and from healthy controls. Serum her-2/neu and survivin levels were determined using an enzyme-linked immunosorbent assay. There was no difference in the levels of serum her-2/neu and survivin between the breast cancer patients and the control group. Serum her-2/neu concentration showed moderate correlations with disease stage and the Ki-67 level, and the serum survivin level showed a moderate correlation with progesterone receptor concentration. Serum levels of her-2/neu and survivin were not significantly related to age and histological parameters in patients with early-stage breast cancer. However, much research continues on the prognostic value of serum her-2/neu and survivin levels, and important new knowledge may ultimately emerge.
Introduction
Breast cancer is the most common malignancy among women, accounting for nearly one in three cancers diagnosed in females in the USA; it is the second leading cause of cancer death. 1 Clinical parameters, such as tumour size and lymph-node status, have been used as prognostic factors in breast cancer; however, it has been necessary to establish additional factors in order to attempt to classify patients according to indicators such as the recurrence risk and the type of therapy to administer. 2 Survivin is encoded by a member of the inhibitor of apoptosis (IAP) gene family, which has been implicated in both the inhibition of apoptosis and the regulation of mitosis. 3 Unlike bcl-2 and other IAP proteins, survivin is undetectable in terminally differentiated adult tissues, but becomes G Goksel, F Taneli, R Uslu et al. Serum her-2/neu and survivin levels notably expressed in most common human cancers in vivo. 4 -6 Survivin plays multiple roles in malignancy, including the inhibition of apoptosis, the stimulation of proliferation and the promotion of angiogenesis. High levels of survivin are detected in many human cancer types, including 70% of breast cancers. 7, 8 Many studies have found that survivin expression is related to an unfavourable prognosis in patients with various solid tumours. 9 Survivin is currently being investigated both as a target for new anticancer treatments and as a new tumour marker.
The her-2/neu proto-oncogene encodes a 185-kDa transmembrane receptor with tyrosine kinase activity. Amplification of the her-2/neu gene and/or over-expression of the protein correlates with a poor prognosis for patients with breast cancer in most studies. Over-expression of her-2/neu might influence a number of aspects of the breast cancer phenotype. These include reduced endocrine responsiveness, increased metastatic ability and drug resistance. The extracellular domain of the her-2/neu protein (her-2/neu ECD) is cleaved and shed from the receptor and can be detected in serum as a protein of approximately 105 kDa. The shedding is regulated actively by a proteolytic process. 10 The presence of increased her-2/neu ECD levels in serum is reported to be correlated with a greater tumour burden. 11 -13 The aim of the present study was to investigate the relationship of known histological parameters, age and menopausal status with serum survivin and her-2/neu concentrations and, consequently, to determine whether serum her-2/neu concentration can be used as an alternative prognostic factor to tissue her-2/neu status in early-stage breat cancer.
Materials and methods

PATIENTS
Female patients with unilateral, resectable breast cancer who underwent surgery for the removal of a primary tumour were included in this study. Healthy female volunteers were recruited as controls.
Exclusion criteria included metastasis, severe renal, haematological, hepatic and cardiac dysfunction, and metabolic bone disease. The study was performed in conformity with the Declaration of Helsinki II and was approved by the Ethical Review Committee of the Faculty of Medicine of Celal Bayar University, Manisa. All subjects gave written informed consent to participation in the study.
MEASUREMENT OF SERUM SURVIVIN AND HER-2/NEU LEVELS
Serum samples were collected from breast cancer patients on first admission before adjuvant chemotherapy. Venous blood samples were obtained from patients and normal healthy controls between 07:00 and 10:00 h after overnight and morning fasting of approximately 12 h. Samples were centrifuged at 4°C and the sera were stored at -70°C for batch assessments.
Total human serum survivin concentrations were analysed by an enzyme-linked immunosorbent assay (ELISA) method using commercial reagents (TiterZyme ® EIA; Assay Designs, Ann Arbor, Michigan, USA). A human her-2/neu ELISA kit (human sp185 HER-2 ; Bender MedSystems, Vienna, Austria) was used for the quantitative determination of her-2/neu in serum samples.
PATHOLOGICAL ASSESSMENT
Sections (5 µm thick) were taken from formalin-fixed paraffin-embedded tissue blocks. They were stained routinely with G Goksel, F Taneli, R Uslu et al. Serum her-2/neu and survivin levels haematoxylin and eosin. In each case, grading of tumours was made according to the modified Bloom-Richardson system, which is based on tubule formation, mitotic rate and pleomorphism of tumour cells. The most representative tumour-containing block was used in immunostaining, which was based on the standard streptavidinbiotin immunoperoxidase method. The immunohistochemical profile included reagents such as oestrogen and progesterone receptors, p53, Ki-67 and her-2/neu.
Evaluation of immunohistochemical staining
Except for her-2/neu, clear nuclear staining was considered positive. Positivity was expressed as the absolute percentage of positive tumour cell nuclei among all tumour cells, counting in at least 10 highpower fields. With regard to her-2/neu, however, scoring was based on the percentage and staining intensity of cells showing complete membrane staining. With this scoring system, tumours were categorized as -, +, ++ and +++. This scoring system has some inherent subjectivity.
STATISTICAL ANALYSIS
SPSS ® version 10.0 (SPSS, Chicago, Illinois, USA) was used for statistical analysis. Normally distributed variables are reported as mean ± SD and variables with a skewed distribution are reported as median and range.
Quantitative variables were compared between two groups using the Student's t-test for normally distributed variables and the Mann-Whitney U-test for variables with a skewed distribution. Quantitative variables were compared between three or more groups using the Kruskal-Wallis test for variables with skewed distribution. Correlations between the variables were calculated using Pearson's correlation coefficient. A Pearson's correlation coefficient of 0 indicates no relationship and one > 0.75 indicates a strong relationship. All P-values were two sided and P-values < 0.05 were considered to be statistically significant. Table 1 .
Results
The intra-assay coefficients of variation for the survivin assay were 2.4, 1.3 and 1.8% at concentrations of 117, 217 and 693 pg/ml, respectively. The inter-assay coefficients of variation were 15.9, 17.5 and 5.9% at concentrations of 142, 278 and 700 pg/ml, respectively.
The intra-assay coefficients of variation for the her-2/neu assay were 0.8 and 2.2% at concentrations of 4.15 and 34.88 ng/ml, respectively. The inter-assay coefficients of variation were 4.3 and 3.6% at concentrations of 3.95 and 36.39 ng/ml, respectively.
Levels of serum her-2/neu and survivin in patients with early-stage breast cancer and in healthy controls are shown in Table 2 . There was no significant difference in serum her-2/neu or in survivin levels between the early-stage breast cancer patients and the controls.
None of the prognostic parameters analysed correlated significantly with serum her-2/neu concentrations, except for disease (Table 3 ). There was also a moderate correlation between serum survivin level and progesterone receptor level (r = 0.363). The serum levels of her-2/neu and survivin were not found to be significantly related to age and histological parameters in patients with early-stage breast cancer (Table 4 ).
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Discussion
This study investigated serum levels of her-2/neu and survivin and their relationship with clinicopathological factors in patients with early-stage breast cancer. To the authors' knowledge this is the first report on serum her-2/neu and survivin levels in early-stage breast cancer patients.
The her-2/neu status of a patient is usually evaluated by means of immunohistochemistry of the early-stage breast cancer specimen, but this technique requires a high-quality tissue sample, which may not be available. An automated ELISA assay has been developed for measuring circulating concentrations of the her-2/neu oncoprotein. Some of the advantages of this method are that it is reproducible, quantitative and objective, and that blood is collected routinely in the physician's office before administration of chemotherapy. The study aimed to determine whether serum her-2/neu concentration can be used as an alternative prognostic factor to tissue her-2/neu status in early-stage breast cancer. Kong et al. showed that serum her-2 concentration cannot be substituted for immunohistochemistry or fluorescent in situ hybridization to evaluate her-2 status, nor can it be used as a diagnostic tumour marker in early-stage breast cancer when the low prevalence of serum her-2 elevation is 14 On the other hand, another study from the same group showed a correlation with the levels of serum her-2/neu and tissue her-2/neu in metastatic breast cancer patients. 15 Pallud et al. 16 demonstrated that the serum her-2/neu level is correlated with the size and histological grade of the tumour in primary breast cancer patients. They concluded that the serum her-2/neu level can be used in the absence of tissue samples for immunohistochemical evaluation of her-2/neu levels.
In one study, tissue survivin expression was tested with immunohistochemistry in primary breast cancer patients and no correlation was found between survivin expression and any histological parameter, such as tumour size, p53 expression, and oestrogen receptor and progesterone receptor levels. 17, 18 In the present study, the same conclusions were drawn for serum survivin levels; however, another study showed that high tissue survivin expression was correlated with high nuclear grade, negative hormone receptor status and her-2/neu over-expression in primary breast cancer patients. 19 It seems that there are conflicting data in the literature regarding tissue survivin expression and its prognostic value in primary breast cancer patients. Although some inconsistent reports exist, an overwhelming number of reports support the idea that survivin expression in cancer is associated with poor prognosis, cancer progression/recurrence, drug resistance and a short patient survival period.
The present study failed to find any correlation with the levels of tissue her-2/neu and serum her-2/neu levels with any of the other variables we measured in early-stage breast cancer patients. There was also no significant difference in the levels of serum her-2/neu between breast cancer patients and healthy controls. No statistically significant relationships were found between the levels of serum her-2/neu and various characteristics of the patients and their disease, such as disease stage, age, menopausal status and hormone receptor status.
In conclusion, the present study investigated whether serum survivin level can be used as an easy and quick alternative method for analysing survivin expression in tumour tissue. No significant difference in the serum survivin levels between breast cancer patients and healthy controls was found; consequently, serum survivin levels cannot be used as a tumour marker in earlystage breast cancer patients. However, it is possible that future large-scale research studies may make important discoveries about the prognostic value of serum her-2/neu and survivin levels.
